Lipoprotein removal by soluble enzymes
AssigneeMit
InventorsRobert S. Lees, Robert S. Langer, Jr., Regine Labeque, Claudy J. P. Mullon
Life of this patent
Estimating the term…
Abstract
A therapeutically effective amount of soluble phospholipase A.sub.2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospholipase A.sub.2 modifies the plasma LDL by hydrolyzing the phospholipids present in LDL. As a result, the modified LDL is rapidly removed from the bloodstream by the catabolic processes.
Claims12
A process for lowering the level of low density lipoproteins ("LDL") in a subject's blood, which process comprises
- administering a therapeutically effective amount of the enzyme phospholipase A.sub.2 into the subject to hydrolyze the sn-2 fatty acyl ester bond of phosphoglycerides of the LDL in such a form that they are subject to rapid removal by the in vivo catabolic processes.
A process for lowering the level of low density lipoproteins ("LDL") in blood, which process comprises exposing the LDL to the enzyme phospholipase A.sub.2, thereby hydrolyzing the sn-2 fatty acyl ester bond of phosphoglycerides of the LDL in such a form that they are subject to rapid removal by the in vivo catabolic processes.
Dependencies are inferred from the claim text.